Surasakdi Wongratanacheewin (Thailand) showed how Temozolomide in vitro a helminth parasite, Opisthorchis Viverrini, uses its antigens to modulate the host immune response by stimulating regulatory cytokines leading to evasion of the host

immune response by and survival of the parasite. The theme of the third symposium was Treg cells, cytokines and inflammation, which started with a lecture by Bhagirath Singh (Canada) who highlighted the properties of two populations of Th17 cells — one being pathogenic and the other protective. In addition, Bhagirath Singh stressed the controversial nature of Th17 cells in autoimmunity. Cindy Mah (Australia) introduced a relatively recently identified T-cell subset, i.e. T follicular

helper (Tfh) cells, a subset of CD4+ T cells that localize to B-cell follicles where they are positioned so as to provide help to B cells. Nicholas King reported that timed interference of specific leukocyte subset migration can significantly increase survival without compromising sterilizing immunity in lethal neurotropic flavivirus infaction. Sudhir Gupta (USA) and Vineeta Bal (India) discussed the impact of ageing on various cell lineages, including T lymphocytes and DCs. The fourth theme focused on tumor and transplant immunology. It started with a lecture by Jonathan Sprent (Australia) who discussed the expansion of T-cell subsets using IL-2-/mab complexes and the implications Fulvestrant nmr of such expanded T-cell subsets for immunity and transplant

tolerance. Rajiv Khanna (Australia) presented that his group, in collaboration with an Australian biotech company (Cellestis Inc.), has successfully developed a novel T-cell-based immune monitoring technology (QuantiFERON-CMV) that allows the identification of high risk transplant patients i.e. those who may develop virus-associated complications post-transplantation. Catherine Fridman (France) showed that in human primary non small cell lung cancers (NSCLCs), the tumor microenvironment may impair Thymidine kinase NK cells locally, making them less prone to kill tumors and hence contributing to cancer progression. Nina Bhardwaj (USA) presented an overview of the tumor microenvironment and showed that tumors secrete factors that modulate both innate and adaptive immunity. Koji Nomota (Japan) introduced the role of probiotics as efficient immunopotentiators, describing their translational role in cancer prevention. Symal Roy (India) presented that the poor stability of peptide-MHC complexes may determine defective cellular immunity in Leishmaniasis. The topic of the fifth symposium was adjuvants and vaccines. During her talk, Olivera Finn (USA) supported the feasibility of vaccinating individuals at high risk for developing cancer in order to prevent its recurrence or progression.

23 In the weighted regression models, survival was similar among the three hypothetical ESA doses (15 000 U/week, 30 000 U/week and 45 000 U/week). In contrast, in the standard unweighted regression model, erythropoietin doses of 10 000–20 000 U/week and <10 000 U/week were associated with 18% and 27% reductions in mortality, respectively, compared with the reference dose of 20 000–30 000 U/week. On the other hand, doses of 30 000–40 000 U/week

and >40 000 U/week were associated with 16% and 26% increases in mortality, respectively. Another this website analysis of 27 791 prevalent haemodialysis patients found that HR estimates were no longer significant when using a marginal structural model that included increasing covariate history and reduced weight truncation.24 The authors concluded that erythropoietin dose was not associated with increased mortality in a marginal structural model analysis that ‘completely’ addressed confounding by learn more indication. Similarly, Bradbury et al. reported increased mortality with high erythropoietin dose (adjusted HR 1.21, 95% CI 1.15–1.28 per log unit increase) using a Fresenius Medical Care database of 22 955 prevalent haemodialysis patients.25 Temporal association between erythropoietin dose and mortality was assessed by additional analyses by lagging

erythropoietin dose at 1 and 2 months intervals, with haemoglobin values lagged at 2 and 3 months. These lagged, time-dependent analyses did not demonstrate any association between erythropoietin L-gulonolactone oxidase dose and mortality. In contrast, Brookhart et al. characterized each US dialysis centre’s annual anaemia management practice by estimating its typical use of ESAs and iron in 269 717 incident patients in the first 6 months of initiating haemodialysis using US Medicare data.26 Correlation between centre-level patterns of ESA use on 1 year mortality was studied. Mortality rates were highest in patients with

haematocrit levels <30% (2.1%). As the haematocrit increased, mortality rates decreased. Mortality rates for haematocrit levels of 30–32.9%, 33–35.9% and ≥36% were 1.3%, 0.9% and 0.7%, respectively. In patients with haematocrit levels <30%, higher quintiles of ESA dosage were associated with lower mortality. On the other hand, larger doses of ESAs were associated with higher mortality in patients with haematocrit levels of ≥33%. This analysis was performed using centre-level data rather than patient-level data. Hence, these results should be interpreted with caution. Similarly, Regidor et al. analysed a cohort of 58 058 prevalent haemodialysis patients from the DaVita dialysis organization.27 In the time-dependent multivariate adjusted Cox proportional hazard model, all haemoglobin levels below 115 g/L were associated with inferior survival compared with a haemoglobin level of 115–120 g/L. In contrast, inferior survival was observed only when haemoglobin levels were above 135 g/L. Results were similar for cardiovascular deaths.

As shown in Fig. 5, Flt3L gene expression was significantly increased in MPPs from Fli-1∆CTA/∆CTA B6 selleck kinase inhibitor mice compared with that cultured from wild-type B6 mice. The expressions of STAT3, Csf1 and Flt3

were higher in MPPS from Fli-1∆CTA/∆CTA B6 mice compared with that cultured from wild-type B6 mice, though the difference was not statistically significant (Fig. 5). To assess whether Fli-1 directly or indirectly regulates the expression of Flt3L, we analysed the promoter region of the Flt3L gene. There are 15 putative Fli-1 binding sites in the promoter region of the mouse Flt3L gene. We designed 15 pairs of primers to cover these sites, and a ChIP assay was performed to examine if Fli-1 binds to the promoter of Flt3L. The primers used are listed in Table 1. We examined the expression of Fli-1 and Flt3L in MS1 endothelial cell lines by RT-PCR and found that both Fli-1 and Flt3L are expressed in the cell line (data not shown). After immunoprecipitation by a Fli-1-specific antibody with cross-linked protein/DNA complexes from MS1 cell lines, two Fli-1 sites were significantly enriched with specific Fli-1 antibodies as detected by PCR amplification and compared with normal rabbit IgG controls (Fig. 6). These results clearly indicate Fli-1 can directly bind to the promoter of the Flt3L gene and probably regulate the expression of Flt3L. Fli-1 transcription factor regulates the differentiation

and development of haematopoietic lineages, especially megakaryocytic and erythrocytic lineages.[28-30] We previously demonstrated that Fli-1 modulates B-cell development and is implicated in autoimmune this website disease.[22, 26, 27, 31] We report here that Fli-1 also plays an important role in mononuclear phagocyte

development. We found that Fli-1∆CTA/∆CTA mice had significantly increased populations of HSCs and CDPs in BM compared with wild-type littermates (Fig. 1). Therefore, Fli-1 is likely to play an important role in regulating HSC and CDP development. Expression of Fli-1 clearly affects the HSC population and lack of the CTA domain in Fli-1 resulted in the increase of the HSC population. Previous studies have demonstrated that expression of Fli-1 affects development and differentiation Protein kinase N1 of megakaryocytes, erythrocytes, neutrophils and monocytes in Fli-1-deficient or Fli-1 heterozygous mice.[28, 29] Complete Fli-1 deficiency in HSCs resulted in a decrease in neutrophilic granulocyte and monocyte populations in mice.[29] In this report, we used Fli-1ΔCTA/ΔCTA mice with expression of a truncated Fli-1 protein, lacking the C-terminal transcriptional activation domain.[24] Cell proportion and absolute cell number of pDCs, cDCs, pre-cDCs and macrophages in the spleen from Fli-1∆CTA/∆CTA mice were significantly increased when compared with wild-type littermates (Fig. 2). The splenic cDC population can be subdivided into three groups according to their surface markers.

39–41 Voriconazole is neither a substrate nor an inhibitor www.selleckchem.com/products/ABT-263.html of P-gp, nor does it inhibit BCRP.31,42 Posaconazole.  Posaconazole is available as oral suspension and exhibits linear pharmacokinetics with dosages between 50 and 800 mg day−1. However, saturation of absorption occurs at doses exceeding 800 mg day−1.43 Posaconazole absorption and exposure are maximised by dividing the total daily dose into four times daily rather than administering it as a single

dose.44,45 Gastric pH influences absorption, which is optimal under acidic conditions.45 In addition to dividing the dose, the administration of posaconazole oral suspension with or shortly after a meal, or with a liquid nutritional supplement increases the mean plasma exposure up to fourfold

compared with administration in the fasted state.45–47 The effect of food on posaconazole absorption appears to be a result of increased solubilisation of the drug rather than a decrease in gastric emptying.45 Although posaconazole binds extensively (>95%) to plasma proteins, its large estimated volume of distribution suggests that it distributes widely throughout the body.48 Posaconazole CSF concentrations have been reported in a small series of patients (n = 3). Because of the uncontrolled nature of sampling and dosing in these reported cases, no fixed plasma/CNS drug concentration Cilomilast ratio could be deterimed.49 Although posaconazole is a Buspirone HCl lipophilic compound, it is primarily eliminated in the faeces and urine as unchanged drug.50 Approximately 17% of a dose undergoes biotransformation.50 Unlike itraconazole and voriconazole, posaconazole is only minimally (2%) metabolised by CYP.50,51 The majority of posaconazole metabolites are glucuronide conjugates formed via uridine diphosphate glucuronosyltransferase (UGT) pathways.51 The primary metabolite is formed by UGT1A4.51 Although very little posaconazole is metabolised

by CYP, like all azoles, it inhibits hepatic CYP3A4.52 However, in humans, posaconazole has no effect on the activity of other CYP enzymes including CYP2C8/9, CYP1A2, CYP2D6 or CYP2E1.52 Unpublished data regarding the interaction between posaconazole and P-gp demonstrate that it is a P-gp substrate and inhibitor.50,53 Antifungal agents can produce additive toxicities, reduce renal elimination, inhibit biotransformation and interfere with active transport of a variety of other medicines. In contrast, there are far fewer medications that can negatively influence the systemic availability and exposure of antifungal agents by altering pH, or inducing their metabolism. Among the classes of antifungal agents, the polyenes (amphotericin B formulations) are most likely to have interactions with other agents that manifest as additive toxicities.

falciparum-infected groups. Plasma concentrations of CXCL16 in NEG patients were 2930 pg/ml (mean) and the levels were enhanced in those with P. falciparum, to 5160 pg/ml in MM and 8840 pg/ml in SM cases. CXCL9 and CXCL16 levels were clearly higher (P < 0·0001) in SM than in NEG, and CXCL9 levels in SM were higher than those of MM patients (P < 0·0001). At 48–60 h post-anti-malarial treatment (Fig. 3), significantly diminished cytokine concentrations were detected for IL-10, IL-13 and the

chemokines MIG/CXCL9, CXCL16 and MIP-3α/CCL20 (not shown). The mean levels of IL-17F, Romidepsin purchase IL-27, IL-31 and IL-33 did not change at 48–60 h post-anti-malaria treatment and with reduced parasitaemia. In P. falciparum-infected infants, the levels of MIP3-α/CCL20 (r2 = 0·28; P = 0·0002) and MIG/CXCL9 (r2 = 0·33, P = 0·0005) were correlated positively with parasite density, while IL-27 displayed a weak negative correlation (r2 = −0·17; P = 0·01). Naturally acquired protective immunity against malaria requires subclass-specific antibody responses [16–18], and the secretion of cytokines, chemokines and further immune mediators is essential for the regulation both of cellular effector mechanisms against P. falciparum blood-stage parasites and of organ-specific inflammation and pathogenesis [19,20]. In MM and SM infants substantial cytokine Selleckchem GS-1101 and chemokine levels were detected, which disclosed

both innate and memory immune responsiveness. The first parasite encounter and sensitization to P. falciparum antigens may already occur prenatally and continue in infants shortly after birth [21]. P. falciparum infection during pregnancy is a major health problem in our study area [22,23], and prenatal and early life contact with plasmodial antigens has to be considered as a regularity. In infants, antibody responses and pronounced parasite-specific IL-10 production were found to be associated with faster P. falciparum parasite clearance [24], and the higher longevity of regulatory T cell

(Treg)-type IL-10 compared to Th1-type IFN-γ responses [25] suggested that prenatal and early postnatal sensitization with P. falciparum antigens has occurred [26,27]. It is noteworthy that parasite-specific Tyrosine-protein kinase BLK IL-10 responses were observed frequently and of high magnitude in umbilical cord blood cells from newborns of infected mothers [21–23,28]. In the present work, plasma IL-10 levels were not correlated with parasite densities or the infants’ age, and this further supported early life P. falciparum-specific immune sensitization and IL-10 induction. The role of IL-10 in malaria pathogenesis is controversial. High IL-10 levels were associated with cerebral malaria [13], with high parasite density and severe disease in children [29,30], while lower plasma concentrations of IL-10 occurred in those with severe malarial anaemia [13,30].

, 2008; Chiang et al., 2012). The MexEF-OprN and MexXY-oprM efflux systems of P. aeruginosa were shown to be upregulated in response to reactive oxygen species (ROS), and it was proposed that this efflux system exports cellular constituents damaged by ROS (Poole, 2008). This is particularly interesting because bacteria this website in biofilms experience increased oxidative stress (Driffield et al., 2008) which might promote upregulation of these pumps. Thus, in contrast to earlier reported results, it seems that the conventional efflux pumps may play a role in antibiotic tolerance in P. aeruginosa biofilms. Similar

results have been reported in biofilms formed by Escherichia coli isolates from urinary tract infection, where many of the efflux pumps involved in removal of toxic substances, including many antibiotics,

were highly upregulated during biofilm growth (Kvist et al., 2008). Given this increasing evidence for a role of efflux pumps in the tolerance of biofilms to antibiotics, it seems clear that the use of efflux-pump inhibitors might improve the efficacy of antibiotic treatment. Interestingly, it has been shown that inactivation of efflux pumps abolished E. coli biofilm formation (Kvist et al., 2008). The authors speculated that efflux pump activity might be required in the biofilms in order to remove waste products from the bacterial cells. Thus, biofims of CF isolates overexpressing these pumps would show increased tolerance to antipseudomonal drugs, but this awaits confirmation. selleck products The above in vitro studies have shown that the phenotypes that are selected during chronic infection of CF patients with P. aeruginosa (alginate hyperproduction and hypermutabillity) influence the structure and architecture of the biofilms,

thus increasing their tolerance to antimicrobials. In addition, the persistence of the bacteria in biofilms for long periods of time under the selective antibiotic pressure promotes development of mutational resistance mechanisms, making management of the biofilm infection even more difficult. The obvious implications of these studies are early treatment strategies to prevent or eradicate mafosfamide biofilm formation in the very early stages, and maintenance of the intermittent colonization stages for long periods of time (Doring & Hoiby, 2004). This is a strategy proposed in the European consensus for the treatment of P. aeruginosa lung infection of CF patients, which has proved beneficial in several CF centres (Frederiksen et al., 1997; Doring & Hoiby, 2004; Taccetti et al., 2005; Mayer-Hamblett et al., 2012). The efficiency of the treatment depends of the choice of drugs at PK/PD-targeted dosages. Based on in vitro studies the choice of drugs should be made in accordance with the effect on the various biofilm subpopulations: for example, ciprofloxacin which aims at the metabolically active subpopulation and colistin which aims at the metabolically inactive subpopulation (Haagensen et al., 2007; Pamp et al., 2008).

These results suggest that the EBNA1-derived HPV epitope may be a relevant target of EBV-specific CTL responses. To investigate the presentation of the HPV CTL epitope in EBV-positive cells, HLA-B35 or HLA-B53 positive LCLs and BL cells were used as targets of HPV-specific CTL Selleckchem Venetoclax cultures obtained from donors 5 and 7. We found, in the 5-hr 51Cr-release assay that unmanipulated HLA-B35- and HLA-B53-matched LCLs were lysed by HPV-specific CTL cultures whereas BL cells were not recognized, suggesting that the HPV epitope is poorly presented at the surface of BL cells (Fig. 2a,b). To exclude poor sensitivity

to lysis of BL lines, we evaluated the killing of BLs loaded with the synthetic HPV epitope by cytotoxic assay. We found that HPV-pulsed BL cells were recognized by HPV-specific CTLs, indicating that BL cells are sensitive to lysis and able to present the HPV T-cell epitope when exogenously added (Fig. 2b). The IFN-γ production assays have been mainly used in studies documenting the presentation of EBNA1-derived MHC-I-presented CTL epitopes because it is considered a more sensitive indicator

of target cell recognition.10–12 Therefore, we tested whether recognition of EBNA1-expressing BL cells could be revealed by monitoring IFN-γ release in ELISPOT assays. To this end, HPV-specific CTLs and matched LCLs and BL cells were seeded at an effector : target MK-1775 solubility dmso ratio of 10 : 1, and the number of HPV-specific IFN-γ-producing cells was evaluated after 24 hr. As shown in Fig. 2(c), Ribose-5-phosphate isomerase release of IFN-γ was specifically induced by HLA-B35-matched LCLs while HLA-B35-matched and HLA-B53-matched BL cells did not stimulate IFN-γ release, thereby confirming the poor presentation of this epitope in BL cell lines. As a whole, these results demonstrate that the EBNA1-derived HPV epitope is generated and presented in LCLs but not in BL cells. This suggests

that HPV generation does not exclusively depend on the presence of the GAr domain. Loss or down-regulation of HLA class I is one of the routes of immune escape in a variety of human tumours, including BL cell lines.25–28 Therefore, the surface expression of class I molecules in BL cells and LCLs was tested by indirect immunofluorescence. As shown in Fig. 3 and supplementary material, see Table S1, Jijoye cells expressed lower amounts of class I molecules whereas BJAB B95.8 cell lines showed similar levels of total HLA class I molecules, compared with LCLs. However, significant levels of lysis were achieved by the addition of HPV peptide to BL cells, thereby suggesting that sufficient levels of class I molecules were expressed at the cell surface (Fig. 2b).

Loneliness, dementia, depression, Parkinson’s disease, mental stress and compromised gastrointestinal function may result in malnutrition, insufficient protein intake, vitamin deficiencies (especially vitamins A, C and E with antioxidative activities) and deficiencies in trace elements (especially zinc, which is crucial for lymphocyte this website proliferation); all of these factors can result in compromised immune functions [7–10]. In

addition, the elderly are more susceptible to malignancies, severe infections and long-term repeated chronic infections; they experience more trauma, have more major surgeries and have increased incidence of late-stage systemic diseases (renal dysfunction, liver failure and heart failure) and other critical illnesses, all of which may also significantly compromise immune function [11–14]. Moreover, those elderly people who take anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, steroids, antibiotics, antidepressants, antihypertensives or allopurinol may also experience compromised immune function [15, 16]. Thus, even the SENIEUR protocol that has been accepted worldwide cannot meet all of the criteria necessary for selecting healthy PF-2341066 subjects for ageing-related studies. Thus, the SENIEUR protocol was modified and improved with the aim of excluding those factors that could influence cellular immunity. In the present study, 28,376

subjects who were self-reported as healthy were reviewed over an 8-month period. From these, we enrolled 78 subjects aged ≥80 years, 128 subjects aged 60–80 years and 60 subjects aged 20–60 years. Although the number of older subjects, especially those aged ≥80 years, was small and may have

contributed to underestimating the extent of compromised immune function among the elderly, our findings may actually demonstrate the direct oxyclozanide impact of ageing on cellular immunity. As is well known, antigen-presenting cells (APCs) may undergo differentiation and maturation following stimulation with antigens or other stimuli, after which they present antigens to naïve T cells, which become activated T cells. T cell-mediated specific immunity plays a central role in immune responses. T cell activation is primarily characterized by proliferation, and thus, T cell proliferation has been used as a marker of human immune potential. In addition, following treatment with multiple cytokines (recombinant human IL-2, IL-1, γ-INF and CD3 mAb), some PBMCs can become transformed into CD3- and CD56-positive CIK cells, which have both potent antitumour activities as T lymphocytes and non-MHC-restricted tumouricidal activities as NK cells. Thus, CIK tumouricidal activity can also be used as an indicator of human immune function [17, 18]. Our findings revealed that there were no marked differences in the number of peripheral blood total T cells, CD4+ cells, CD8+ cells or CD4+/CD8+ ratios among the subject groups of different ages.

She otherwise had normal growth and development of the right leg. No recurrence was found at 12-year follow-up. Although slight contour asymmetry persists, the bone flap has grown much like the native mandible and the patient has no trismus or difficulties with mastication (Figs. 5A–5C). Melanotic neuroectodermal tumor is a rare entity, with sporadic case reports and series in the literature. Less than 400 cases have been reported to date. First described

in 1918, 90% of the cases are seen Selleckchem Vemurafenib in the head and neck region, with the maxilla being the most affected (68.8%). It is accepted to be of neuroectodermal origin, and as a melanin producing tumor, it produces a blue or black, solid, rapidly growing mass, firmly adhered to the bone. Local excision, with total removal of the mass and curettage of the cavity is the adequate treatment of this benign tumor, but a 10–15% recurrency rate and a 3.2% risk of malignancy have been reported in the literature.[2, 3] In the case reported here, the mass was proportionally large, and a complete resection of the affected bone was preferred for adequate treatment. The feasibility of microsurgical reconstruction in children is no longer a discussion, and although technically challenging, the debate has shifted to evaluating the functional outcome of the reconstructed segment.[4, 5] One particular

concern with these complex reconstructions is how the transplanted tissue will respond to the continuous growth Tyrosine Kinase Inhibitor Library cost of the surrounding structures. We were successful in obtaining near normal growth of the neo-mandible in this case. In adults, the harvest of a fibula free flap does not produce significant function morbidity to the donor leg.[6] In a recent report of 18 fibula flaps used for pediatric mandibular reconstruction,[7] the authors state that the flap would not grow concomitantly with the child. These authors

preserved at least 6 cm of the distal fibula at the donor Edoxaban site in an effort to maintain ankle stability. They were successful in preventing ankle deformities in all of their patients, but other procedures were necessary to correct the length of the transplanted bone. In this case, a long segment of the fibula diaphysis had to be harvested due to the extent of the defect. The proximal and distal ends of the diaphysis of long bones are the regions where most of the bone longitudinal growth occurs through endochondral ossification. We believe that incorporating a more distal segment of the bone into the flap is probably the reason for the continuous growth of the flap and the ankle deformity at the donor site in our case. Other authors have reported similar donor site complications, requiring corrective orthopedic procedures.[8, 9] Interestingly, the flap presented with the expected growth of the mandible segment it replaced. We believe that the same stimulus of the surrounding bone structures and soft tissue that would modulate mandibular growth affected the flap.

The histological analyses were performed by observers who were not aware of the groups of mice from which the samples originated. Images were captured with a digital camera. At least 10 bronchioles with 150–200 μm inner diameter were selected and counted in each slide. For the thickness of tracheal basement membrane, three measures were taken, Compound Library and the average basement membrane thickness was calculated. The area of airway wall (WAt) and area of smooth muscle (WAm) were determined

by morphometric analysis (image-pro plus 6.0; MediaCybernetics Co., Bethesda, MD, USA) on transverse sections after haematoxylin & eosin staining. Basement membrane perimeter (Pbm) was measured for normalization of WAt and WAm. Then we used the ratios of WAt to Pbm (WAt/Pbm) and WAm to

Pbm (WAm/Pbm) to evaluate airway remodelling. Mucus production was determined on transverse sections from the upper left lobe of the lung. The mucus index was calculated as follows: the percentage of the area of mucus on the epithelial surface stained with PAS was determined by image-pro plus 6.0. The area of the respiratory epithelium was outlined, and the image analyser quantified the area of PAS-stained mucus within this reference area. At least 10 bronchioles were counted in each slide. Results were expressed as the percentage of PAS-positive cells/bronchiole, which is calculated from the area of PAS-positive epithelial cells per bronchus divided by the total number of epithelial cells of each bronchiole. Staining with MT was used to determine collagen deposition in the lung. The image-pro plus 6.0 allowed for manual outlining of the trichrome-stained collagen Roxadustat Methisazone layer and computed the area within

the outlined ring of tissue. Briefly, two to four specimens of the MT-stained histological preparations of the lung lobe, in which the total length of the epithelial basement membrane of the bronchioles was 1·0–2·5 mm, were selected and the fibrotic area (stained in blue) beneath the basement membrane in 20 μm depth was measured. The mean score of the fibrotic area divided by the basement membrane perimeter in two to four preparations of one mouse were calculated, then the mean values of subepithelial fibrosis were calculated in 10 mice.21–23 Total RNA was isolated from the right lung tissue using TRIzol Reagent (Invitrogen) according to the manufacturer’s instructions. One millilitre of trizol reagent was added to frozen airway samples and the resulting preparation was ground using a mortar and pestle for 5 min. Chloroform (200 μl) was added and the solution was centrifuged (6750 g, 4°) for 20 min. The aqueous layer was removed by aspiration with a pipette, and an equal volume of isopropanol was added to the aqueous layer. After centrifugation for 17 min as above, the supernatant was discarded and the remaining pellet was washed in 75% ethanol and suspended in 20 μl DNase-free and RNase-free water.